• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Prevention of stroke: what is evidence based?].

作者信息

Lüders S, Schrader J

机构信息

St. Josefs-Hospital, Krankenhausstrasse 13, 49661, Cloppenburg, Deutschland.

出版信息

Internist (Berl). 2009 Dec;50(12):1337-44. doi: 10.1007/s00108-009-2465-0.

DOI:10.1007/s00108-009-2465-0
PMID:19902154
Abstract

On the background of aging population an increase of patients suffering from stroke has to be expected during the next years and decades. Strokes are the 3rd leading cause of death and reason for disability in Germany and many other countries. An effective treatment of the modifiable risk factors hypertension, hyperlipidemia, diabetes mellitus, atrial fibrillation, smoking, alcohol consumption, and adipositas is of enormous impact. Due to the linear relationship between blood pressure and risk of stroke, the treatment of hypertension is the most important and effective one in primary as well as in secondary prevention. Treatment with platelet inhibitors plays an additional important role in secondary prevention. Patients with atrial fibrillation should receive an effective oral anticoagulatory therapy when there are certain risk factors.

摘要

相似文献

1
[Prevention of stroke: what is evidence based?].
Internist (Berl). 2009 Dec;50(12):1337-44. doi: 10.1007/s00108-009-2465-0.
2
Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.32 个国家与急性脑卒中相关的可改变潜在风险因素的全球和区域效应(INTERSTROKE):病例对照研究。
Lancet. 2016 Aug 20;388(10046):761-75. doi: 10.1016/S0140-6736(16)30506-2. Epub 2016 Jul 16.
3
Nutrition and stroke.营养与中风。
Asia Pac J Clin Nutr. 2007;16 Suppl 1:266-74.
4
A benefit-risk assessment of agents used in the secondary prevention of stroke.用于中风二级预防的药物的获益-风险评估。
Drug Saf. 2002;25(13):943-63. doi: 10.2165/00002018-200225130-00005.
5
Medical therapy for secondary prevention of stroke.
Clin Exp Hypertens. 2002 Oct-Nov;24(7-8):555-62. doi: 10.1081/ceh-120015332.
6
Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation: From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation (CONNECT AF).加拿大门诊心房颤动患者心血管危险因素的循证治疗应用:源于促进心房颤动卒中预防的回顾与教育(FREEDOM AF)以及协调全国网络以促使医生参与心房颤动患者的护理与治疗(CONNECT AF)。
Am J Cardiol. 2017 Aug 15;120(4):582-587. doi: 10.1016/j.amjcard.2017.05.027. Epub 2017 Jun 1.
7
New evidence for stroke prevention: scientific review.中风预防的新证据:科学综述。
JAMA. 2002 Sep 18;288(11):1388-95. doi: 10.1001/jama.288.11.1388.
8
Stroke Epidemiology and Risk Factor Management.中风流行病学与风险因素管理
Continuum (Minneap Minn). 2017 Feb;23(1, Cerebrovascular Disease):15-39. doi: 10.1212/CON.0000000000000416.
9
An approach of patients with ischemic stroke to primary and secondary stroke prevention in Poland.波兰缺血性中风患者的一级和二级中风预防方法。
Ann Acad Med Stetin. 2007;53(2):14-9.
10
Strokes in young adults: epidemiology and prevention.年轻成年人中的中风:流行病学与预防
Vasc Health Risk Manag. 2015 Feb 24;11:157-64. doi: 10.2147/VHRM.S53203. eCollection 2015.

本文引用的文献

1
Dabigatran versus warfarin in patients with atrial fibrillation.达比加群与华法林用于房颤患者的比较。
N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
2
Telmisartan to prevent recurrent stroke and cardiovascular events.替米沙坦预防复发性中风和心血管事件。
N Engl J Med. 2008 Sep 18;359(12):1225-37. doi: 10.1056/NEJMoa0804593. Epub 2008 Aug 27.
3
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.他汀类药物14项随机试验中18686例糖尿病患者降脂治疗的疗效:一项荟萃分析。
Lancet. 2008 Jan 12;371(9607):117-25. doi: 10.1016/S0140-6736(08)60104-X.
4
Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis.短暂性脑缺血发作后早期的卒中风险:一项系统评价和荟萃分析。
Lancet Neurol. 2007 Dec;6(12):1063-72. doi: 10.1016/S1474-4422(07)70274-0. Epub 2007 Nov 13.
5
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.老年房颤患者华法林治疗第一年的大出血情况及耐受性
Circulation. 2007 May 29;115(21):2689-96. doi: 10.1161/CIRCULATIONAHA.106.653048. Epub 2007 May 21.
6
Drug therapy for the secondary prevention of stroke in hypertensive patients: current issues and options.高血压患者卒中二级预防的药物治疗:当前问题与选择
Drugs. 2007;67(7):955-63. doi: 10.2165/00003495-200767070-00001.
7
Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.希美加群与华法林用于房颤患者二级卒中预防的比较:SPORTIF III和V临床试验的汇总分析
Stroke. 2007 Mar;38(3):874-80. doi: 10.1161/01.STR.0000258004.64840.0b. Epub 2007 Jan 25.
8
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.抗高血压药物临床试验中的新发糖尿病:一项网状Meta分析。
Lancet. 2007 Jan 20;369(9557):201-7. doi: 10.1016/S0140-6736(07)60108-1.
9
Discontinuation of statin treatment in stroke patients.
Stroke. 2006 Oct;37(10):2640-3. doi: 10.1161/01.STR.0000240690.69406.28. Epub 2006 Aug 31.
10
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).卒中后发病率和死亡率,依普罗沙坦与尼群地平用于二级预防的比较:一项前瞻性随机对照研究(MOSES)的主要结果
Stroke. 2005 Jun;36(6):1218-26. doi: 10.1161/01.STR.0000166048.35740.a9. Epub 2005 May 5.